JV Endocrino: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
JV Endocrino
Largest movements
- Cash +€223,996
up €223,996 (+266%), from €84,175 to €308,171
mainly Net result for the year (+€199,916) and Tax, wage and social debts (+€47,054)
- Tangible fixed assets +€20,924
up €20,924 (+410%), from €5,101 to €26,025
- Reserves +€200,000
up €200,000 (+328%), from €61,000 to €261,000
- Tax, wage and social debts +€47,054
up €47,054 (+278%), from €16,898 to €63,951
- Gross operating margin +€198,921
up €198,921 (+282%), from €70,547 to €269,467
- Taxes +€47,168
up €47,168 (+316%), from €14,912 to €62,080
- Depreciation +€6,453
up €6,453 (+401%), from €1,608 to €8,061
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €89,558 | €335,433 | +€245,875 | +275% |
| Fixed assets | 21/28 | €5,101 | €26,025 | +€20,924 | +410% |
| Tangible fixed assets | 22/27 | €5,101 | €26,025 | +€20,924 | +410% |
| Furniture and vehicles | 24 | €5,101 | €26,025 | +€20,924 | +410% |
| Current assets | 29/58 | €84,457 | €309,408 | +€224,951 | +266% |
| Amounts receivable within one year | 40/41 | - | €1,236 | +€1,236 | |
| Trade receivables | 40 | - | €1,236 | +€1,236 | |
| Cash at bank and in hand | 54/58 | €84,175 | €308,171 | +€223,996 | +266% |
| Deferred charges and accrued income | 490/1 | €282 | €0 | -€282 | -100% |
| Total equity and liabilities | 10/49 | €89,558 | €335,433 | +€245,875 | +275% |
| Equity | 10/15 | €66,513 | €266,429 | +€199,916 | +301% |
| Contributions | 10/11 | €5,000 | €5,000 | = | 0.0% |
| Reserves | 13 | €61,000 | €261,000 | +€200,000 | +328% |
| Distributable reserves | 133 | €61,000 | €261,000 | +€200,000 | +328% |
| Profit (loss) carried forward | 14 | €513 | €429 | -€84 | -16.4% |
| Amounts payable | 17/49 | €23,044 | €69,003 | +€45,959 | +199% |
| Amounts payable within one year | 42/48 | €22,620 | €68,724 | +€46,104 | +204% |
| Trade debts | 44 | €1,603 | €1,087 | -€516 | -32.2% |
| Suppliers | 440/4 | €1,603 | €1,087 | -€516 | -32.2% |
| Taxes, remuneration and social security | 45 | €16,898 | €63,951 | +€47,054 | +278% |
| Taxes | 450/3 | €16,898 | €63,951 | +€47,054 | +278% |
| Other amounts payable | 47/48 | €4,119 | €3,686 | -€434 | -10.5% |
| Accrued charges and deferred income | 492/3 | €424 | €279 | -€145 | -34.2% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €1,608 | €8,061 | +€6,453 | +401% |
| Other operating charges | 640/8 | €115 | €126 | +€11 | +9.6% |
| Non-recurring operating charges | 66A | €196 | - | -€196 | |
| Gross operating margin | 9900 | €70,547 | €269,467 | +€198,921 | +282% |
| Operating profit (loss) | 9901 | €68,627 | €261,280 | +€192,653 | +281% |
| Financial income | 75/76B | - | €823 | +€823 | |
| Recurring financial income | 75 | - | €823 | +€823 | |
| Financial charges | 65/66B | €217 | €107 | -€110 | -50.6% |
| Recurring financial charges | 65 | €217 | €107 | -€110 | -50.6% |
| Profit (loss) for the period before taxes | 9903 | €68,410 | €261,996 | +€193,586 | +283% |
| Income taxes | 67/77 | €14,912 | €62,080 | +€47,168 | +316% |
| Profit (loss) for the period | 9904 | €53,498 | €199,916 | +€146,418 | +274% |
| Profit (loss) for the period to be appropriated | 9905 | €53,498 | €199,916 | +€146,418 | +274% |
Source: filed annual accounts (NBB), financial years ended 30 September 2024 and 30 September 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 23 October 2026 via checked.be.